Scott Eggener, MD

GU Oncology Now

Scott Eggener, MD, of UChicago Medicine, provides an overview of advancements in and patient perspectives on Grade Group 1 prostate cancer and discusses the minimization of unnecessary treatment by promoting active surveillance.Patients with prostate cancer were found to be overtreated for their low-risk disease, and so the Gleason scoring system was relabeled as the Grade Group scoring system. Active surveillance is considered the preferred management approach in most guidelines for Grade Group 1 prostate cancer due to evidence that patients have better outcomes when they do not undergo unnecessary treatment for low-risk cancer.Dr. Eggener is vice-chair of the Section of Urology, director of the High-Risk and Advanced Prostate Cancer Clinic, and the Bruce and Beth White Family Professor of Surgery at UChicago Medicine.

Dr. Scott Eggener Discusses Grade Group 1 Prostate Cancer

Video Insights

Dr. Scott Eggener, of UChicago Medicine, provides an overview of the advancements in and patient perspectives on Grade Group 1 prostate cancer.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe